Rallybio Corporation
RLYB
$15.92
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.91% | 12.71% | 154.52% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.91% | 12.71% | 154.52% | -- | -- |
| Cost of Revenue | -47.75% | -55.61% | -52.12% | -39.38% | -11.42% |
| Gross Profit | 49.18% | 56.47% | 53.29% | 40.97% | 12.92% |
| SG&A Expenses | -15.86% | -25.69% | -27.19% | -34.23% | -32.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.79% | -47.05% | -45.00% | -37.79% | -30.91% |
| Operating Income | 38.65% | 47.59% | 45.81% | 38.89% | 31.72% |
| Income Before Tax | 84.46% | 78.84% | 43.62% | 36.83% | 22.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.46% | 78.84% | 43.62% | 36.83% | 22.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.46% | 78.84% | 43.62% | 36.83% | 22.52% |
| EBIT | 38.65% | 47.59% | 45.81% | 38.89% | 31.72% |
| EBITDA | 38.67% | 47.66% | 45.86% | 38.94% | 31.75% |
| EPS Basic | 85.03% | 79.93% | 47.84% | 42.38% | 27.35% |
| Normalized Basic EPS | 41.22% | 50.87% | 49.37% | 43.58% | 35.45% |
| EPS Diluted | 85.03% | 79.93% | 47.84% | 42.38% | 27.35% |
| Normalized Diluted EPS | 41.22% | 50.87% | 49.37% | 43.58% | 35.45% |
| Average Basic Shares Outstanding | 3.43% | 5.41% | 7.71% | 9.76% | 7.65% |
| Average Diluted Shares Outstanding | 3.43% | 5.41% | 7.71% | 9.76% | 7.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |